Diabetes is a complex and challenging condition that affects over 37 million people in the US alone, with devastating complications. One of the most significant complications is diabetic retinopathy, which affects 9% of adults aged 45 and over with diagnosed diabetes and is a leading cause of blindness in the US. The financial and personal costs of this condition are staggering, and given the low adherence to recommended screening protocols and high risk of developing diabetic retinopathy, better screening options are urgently needed.
Diabetic retinopathy imposes a significant financial burden on individuals and society as a whole. The Centers for Disease Control and Prevention estimates that diabetes-related blindness costs the US healthcare system over $500 million annually . Direct medical costs associated with treating diabetic retinopathy are higher than those associated with diabetes alone , including expenses for medications, surgeries, and doctor visits. In addition, the condition imposes indirect costs such as lost productivity and reduced economic output. Moreover, individuals with diabetic retinopathy may face high out-of-pocket costs, which can create a significant financial burden for them and their families.
But the cost of diabetic retinopathy goes beyond just financial implications. The personal costs of this condition are equally significant. Losing one's vision can have a profound impact on a person's quality of life, affecting their ability to perform daily activities, such as driving, reading, and even recognizing faces. It can also lead to social isolation, depression, and a loss of independence. People with vision loss may also require assistance from family members or caregivers, which can place a strain on personal relationships.
The good news is that early detection and treatment of diabetic retinopathy can significantly mitigate the risk of blindness. By detecting the disease in its early stages, treatment is more likely to be successful. However, since patients are typically asymptomatic in the early stages, regular eye exams are crucial for early detection. Unfortunately, more than 50% of patients do not adhere to the recommended screening, often due to lack of access to traditional specialist screenings.
One promising approach to address this issue is the use of AI-based diagnostic screening. With artificial intelligence, diagnostic screening can be fully automated and performed in primary care, avoiding the need for referrals to eye specialists. This means patients can be screened at their point of care, and only referred to specialists for treatment, reducing waiting times and referral costs.
AI-based screening solutions have numerous advantages over traditional methods. They offer convenient, on-the-spot diagnosis without the need for multiple appointments or referrals, saving time and reducing the burden on patients and healthcare providers. They are also cost-effective, reducing the need for ophthalmologist referrals and lowering healthcare costs. Additionally, AI-based screening solutions improve access to care by providing screening at the patient's point-of-care, alleviating the burden of seeing a specialist for a dilated eye exam. By leveraging these technologies, we can improve early detection and treatment of diabetic retinopathy, ultimately reducing the burden of this disease for patients and society as a whole.
Patient education and awareness are also crucial to curbing the high cost of diabetic eye disease. Many people with diabetes are not aware of the importance of regular eye exams or the availability of AI-based screening solutions. Primary care providers and insurers can play a key role in educating patients about the importance of regular eye exams and promoting the use of AI-based screening solutions.
In conclusion, diabetic retinopathy is a serious and costly complication of diabetes. Early detection and intervention are crucial to preventing vision loss and reducing healthcare costs. AI-based diagnostic screening solutions offer a promising approach to early detection and can improve access to care and reduce healthcare costs. By promoting patient education and effective diabetes management, we can help prevent diabetic retinopathy and improve the lives of people living with diabetes.
Zhang X, Low S, Kumari N, Wang J, Ang K, Yeo D, Yip CC, Tavintharan S, Sum CF, Lim SC. Direct medical cost associated with diabetic retinopathy severity in type 2 diabetes in Singapore. PLoS One. 2017 Jul 10;12(7):e0180949. doi: 10.1371/journal.pone.0180949. PMID: 28700742; PMCID: PMC5507311.